Core Viewpoint - Pharmaceutical stocks have risen significantly, driven by regulatory changes aimed at expediting the approval of urgently needed foreign drugs in China [1] Group 1: Stock Performance - Companies such as 加科思-B (01167) increased by 8.71% to HKD 7.24, 和铂医药-B (02142) rose by 7.61% to HKD 14.28, 复宏汉霖 (02696) gained 5.25% to HKD 67.2, and 映恩生物-B (09606) climbed 4.88% to HKD 365.6 [1] Group 2: Regulatory Changes - The National Medical Products Administration (NMPA) has optimized the review and approval process for urgently needed foreign drugs that are already on the market, aiming to meet the clinical needs of patients [1] - The NMPA emphasizes a clinical value-oriented approach, encouraging applicants to conduct global synchronous research and simultaneous submissions in China [1] - Original and generic drugs that are urgently needed and meet the criteria can be included in the priority review and approval category [1] Group 3: Market Outlook - Huatai Securities believes that the valuation of innovative drugs in the Hong Kong market remains attractive compared to global peers, attributing the liquidity discount to the decline in innovative drugs during November and December [1] - The firm anticipates that the ongoing liquidity recovery, along with continued business development (BD) activities and the upcoming JPM conference and annual report season, will boost the innovative drug sector [1] - The upward trend in the innovative drug sector is expected to continue as liquidity improves at the beginning of the year [1]
医药股再度走高 国家药监局进一步优化审评审批 机构看好创新药迎多重催化